Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Preliminary results reported from phase II trials of Vitrase

March 6, 1998

Improved vision in AMD patients in phase I/II using PhotoPoint technology

Feb. 25, 1998

Allergan's new antiglaucoma agents

Feb. 20, 1998

Genetic basis for RP described

Feb. 5, 1998

FDA issues approvable letter for BioLon

Feb. 4, 1998

Novo Nordisk discloses peripheral muscarinic cholinergic agonists

Jan. 13, 1998

NIH contemplates licensing ophthalmic technology to GenVec

Jan. 7, 1998

Alcon discloses new antiglaucoma agents in patent literature

Jan. 2, 1998

Medarex's secondary cataract product enters phase III

Dec. 19, 1997

Pharmacyclics grants Alcon rights to Lu-Tex

Dec. 19, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
GLP-1s need technologies for long-term use
BioWorld
For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
UTRN gene involved in arthrogryposis, study finds
BioWorld Science
Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...
HMNC raises $50M series B to prep depression drugs for phase III
BioWorld
HMNC Brain Health GmbH has raised $50 million in the first close of a series B, enabling the company to prepare the way for phase III trials of its two lead...
CFTX-2034 successfully shows promise for post-bariatric hypoglycemia in preclinical research
BioWorld Science
Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist...